Upgrade to SI Premium - Free Trial

Pfizer (PFE) Reports Marketing Authorization in European Union from Euro Commission for Moderately to Severely Active Ulcerative Colitis

August 1, 2018 6:30 AM
Pfizer Inc. (NYSE: PFE) announced today that the European Commission (EC) has approved XELJANZ® (tofacitinib citrate) 10 mg twice-daily (BID) ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Categories

FDA Management Comments

Next Articles